Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Profound Medical Corporation

http://www.profoundmedical.com/

Latest From Profound Medical Corporation

Finance Watch: Biotech Stocks Stabilize At The End Of A Rocky Week

Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.

Financing Business Strategies

Finance Watch: Days Of Reckoning As Biopharma Valuations, Fundraising Opportunities Fluctuate

Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.

Financing Leadership

Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer

The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.

Market Intelligence Cancer

Market Intel: New Thermal Therapies Blaze Trail In Fast-Growing Cancer Ablation Market

Cancer rates are rising worldwide and as diagnostic techniques continue to improve, new surgical ablation devices are becoming crucial weapons in the growing arsenal of cancer treatment tools. These devices allow doctors to burn away tumors with precision, speed and safety, without the side-effects that patients undergoing radical cancer therapy often experience. This article provides an overview of the cancer ablation market, highlights the key players working on these devices and discusses their potential applications. It also includes critical insights from a leading interventional urologist on the pros and cons of using these various technologies in treating prostate cancer.

Cancer Surgical Procedures
See All

Company Information

  • Industry
  • Medical Devices
  • Medical Devices
    • Consumables, Central Supplies
    • Implantable Devices
    • Infection Control-Sterilization
    • Infusion Therapy Equipment and Supplies
    • Laser
    • Monitoring Equipment & Devices
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
  • Other Names / Subsidiaries
    • Profound Medical GmbH Mira IV Acquisition Corp. Profound Medical Inc., Profound Medical (U.S.) Inc., Profound Medical Oy
UsernamePublicRestriction

Register